A 2025 Kaiser Family Foundation (KFF) poll suggests that about one in eight adults are taking a GLP-1 medication
Chronic GI conditions often require 4-12 weeks of consistent oral use
The funding sources had no input in the design and conduct of this study, in the collection, analysis and interpretation of the data or in the preparation, review or approval of the manuscript
This is where antioxidants come in
Decrease in lung inflammation is why GLP-1 meds work for asthma patients In a fun twist, that is beyond the scope of this post but worth mentioning, in the rodent models lacking GLP-1R in the brain were given tirzepatide, a GLP-1 & GIP agonist, then some of the anti-inflammatory benefits returned, suggesting GIP has an anti-inflammatory role as well
Proper injection technique and site selection are key to comfort, absorption, and consistent results